Literature DB >> 11073368

Neuropathy in HIV infection.

H Manji1.   

Abstract

Peripheral nerve complications in patients infected with HIV usually result from the virus itself, or are due to some of the antiretroviral drugs (zalcitabine, didanosine or stavudine). It may be difficult to distinguish between these two aetiologies on clinical or neurophysiological criteria. Since they are a significant cause of morbidity, a number of studies have looked at agents used for symptomatic control. More recently, there has been a focus on treatments that improve nerve function, including recombinant human nerve growth factor and the reduction of HIV viral load with antiretroviral drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11073368     DOI: 10.1097/00019052-200010000-00014

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  14 in total

Review 1.  Diagnosis of acute neuropathies.

Authors:  Clarissa Crone; Christian Krarup
Journal:  J Neurol       Date:  2007-09-21       Impact factor: 4.849

2.  Controlling neuropathic pain in HIV.

Authors:  Susama Verma; Lydia Estanislao; Letty Mintz; David Simpson
Journal:  Curr HIV/AIDS Rep       Date:  2004-09       Impact factor: 5.071

3.  Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides.

Authors:  Aubin Moutal; Wennan Li; Yue Wang; Weina Ju; Shizhen Luo; Song Cai; Liberty François-Moutal; Samantha Perez-Miller; Jackie Hu; Erik T Dustrude; Todd W Vanderah; Vijay Gokhale; May Khanna; Rajesh Khanna
Journal:  Br J Pharmacol       Date:  2017-03-17       Impact factor: 8.739

4.  Dorsal root ganglia damage in SIV-infected rhesus macaques: an animal model of HIV-induced sensory neuropathy.

Authors:  Tricia H Burdo; Krystyna Orzechowski; Heather L Knight; Andrew D Miller; Kenneth Williams
Journal:  Am J Pathol       Date:  2012-02-07       Impact factor: 4.307

5.  Niflumic acid, a TRPV1 channel modulator, ameliorates stavudine-induced neuropathic pain.

Authors:  Lovish Marwaha; Yashika Bansal; Raghunath Singh; Priyanka Saroj; Rupinder Kaur Sodhi; Anurag Kuhad
Journal:  Inflammopharmacology       Date:  2016-10-18       Impact factor: 4.473

6.  Controlling Neuropathic Pain in HIV.

Authors:  Susama Verma; Lydia Estanislao; Letty Mintz; David Simpson
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

7.  Animal models of HIV peripheral neuropathy.

Authors:  Tricia H Burdo; Andrew D Miller
Journal:  Future Virol       Date:  2014-05-01       Impact factor: 1.831

8.  Dissecting the role of the CRMP2-neurofibromin complex on pain behaviors.

Authors:  Aubin Moutal; Yue Wang; Xiaofang Yang; Yingshi Ji; Shizhen Luo; Angie Dorame; Shreya S Bellampalli; Lindsey A Chew; Song Cai; Erik T Dustrude; James E Keener; Michael T Marty; Todd W Vanderah; Rajesh Khanna
Journal:  Pain       Date:  2017-11       Impact factor: 6.961

9.  Betulinic acid, derived from the desert lavender Hyptis emoryi, attenuates paclitaxel-, HIV-, and nerve injury-associated peripheral sensory neuropathy via block of N- and T-type calcium channels.

Authors:  Shreya S Bellampalli; Yingshi Ji; Aubin Moutal; Song Cai; E M Kithsiri Wijeratne; Maria A Gandini; Jie Yu; Aude Chefdeville; Angie Dorame; Lindsey A Chew; Cynthia L Madura; Shizhen Luo; Gabriella Molnar; May Khanna; John M Streicher; Gerald W Zamponi; A A Leslie Gunatilaka; Rajesh Khanna
Journal:  Pain       Date:  2019-01       Impact factor: 7.926

10.  A modulator of the low-voltage-activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies.

Authors:  Song Cai; Peter Tuohy; Chunlong Ma; Naoya Kitamura; Kimberly Gomez; Yuan Zhou; Dongzhi Ran; Shreya Sai Bellampalli; Jie Yu; Shizhen Luo; Angie Dorame; Nancy Yen Ngan Pham; Gabriella Molnar; John M Streicher; Marcel Patek; Samantha Perez-Miller; Aubin Moutal; Jun Wang; Rajesh Khanna
Journal:  Pain       Date:  2020-11       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.